Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report

COVID-19

Authors

  • Hareton Teixeira Vechi Universidade Federal do Rio Grande do Norte, Escola Multicampi de Ciências Médicas do Rio Grande do Norte, Caicó, Rio Grande do Norte, Brazil http://orcid.org/0000-0001-7845-3921
  • Lucas Rodrigues Maia Universidade Federal do Rio Grande do Norte, Faculdade de Medicina, Natal, Rio Grande do Norte, Brazil http://orcid.org/0000-0002-4896-6459
  • Manoela do Monte Alves Universidade Federal do Rio Grande do Norte, Centro de Ciências da Saúde, Departamento de Infectologia, Natal, Rio Grande do Norte, Brazil http://orcid.org/0000-0003-2485-3502
  • João Firmino Rodrigues-Neto Universidade Federal do Rio Grande do Norte, Escola Multicampi de Ciências Médicas do Rio Grande do Norte, Caicó, Rio Grande do Norte, Brazil; Universidade Federal do Rio Grande do Norte, Instituto de Medicina Tropical do Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil http://orcid.org/0000-0001-8897-4341

DOI:

https://doi.org/10.1590/s1678-9946202062102%20

Keywords:

COVID-19, Crohn’s disease, TNF inhibitor, SARS-CoV-2

Abstract

COVID-19 is a viral disease caused by SARS-CoV-2 that compromises the host immune response in severe cases, promoting a hyperinflammation that results in acute lung injury and multiple organs failure. In this context, patients presenting with immune-related diseases, such as Crohn’s disease, affected by COVID-19, may have an uncertain prognosis. We report on a case of a young female patient with a severe Crohn’s disease that presented with COVID-19 pneumonia and a favorable outcome even maintaining the use of adalimumab, TNF - alpha inhibitor and prednisone. This case raises the hypothesis that aside from prednisone, TNF-α inhibitors such as adalimumab could be used to stop the progression to COVID-19 complications by blocking the TNF-alpha-driven inflammatory process that occurs in severe COVID-19.

Downloads

Download data is not yet available.

Downloads

Published

2020-12-18

Issue

Vol. 62 (2020)

Section

Case Report

License

Copyright (c) 2021 Revista do Instituto de Medicina Tropical de São Paulo

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Vechi, H. T. ., Maia, L. R. ., Alves, M. do M. ., & Rodrigues-Neto, J. F. . (2020). Favorable outcome of COVID-19 in a young woman with severe Crohn’s disease on regular use of adalimumab and prednisone: a case report: COVID-19. Revista Do Instituto De Medicina Tropical De São Paulo, 62, e102. https://doi.org/10.1590/s1678-9946202062102